Rational Design of Nanobody80 Loop Peptidomimetics: Towards Biased β 2 Adrenergic Receptor Ligands-Reference-Cited by-同舟云学术

Rational Design of Nanobody80 Loop Peptidomimetics: Towards Biased β 2 Adrenergic Receptor Ligands

Published:2017-06-29 Issue:40 Volume:23 Page:9632-9640
ISSN:0947-6539
Container-title:Chemistry – A European Journal
language:en
Short-container-title:Chem. Eur. J.

Author:

Martin Charlotte¹,Moors Samuel L. C.²,Danielsen Mia³,Betti Cecilia¹,Fabris Cecilia¹,Sejer Pedersen Daniel³,Pardon Els⁴,Peyressatre Marion⁵,Fehér Krisztina⁶,Martins José C.⁶,Mosolff Mathiesen Jesper³,Morris May C.⁵,Devoogdt Nick⁷,Caveliers Vicky⁷,De Proft Frank²,Steyaert Jan⁴,Ballet Steven¹^ORCID

Affiliation:

1. Research Group of Organic ChemistryVrije Universiteit Brussel Brussels Belgium

2. Eenheid Algemene Chemie (ALGC)Vrije Universiteit Brussel Brussels Belgium

3. Department of Drug Design and PharmacologyFaculty of Health and Medical SciencesUniversity of Copenhagen Copenhagen Denmark

4. Structural Biology BrusselsVIB-VUB Center for Structural Biology Brussels Belgium

5. Institut des Biomolécules Max Mousseron-IBMM-CNRS-UMR 5247Faculté de PharmacieUniversité de Montpellier Montpellier France

6. NMR and Structure Analysis UnitDepartment of Organic and Macromolecular ChemistryGhent University Gent Belgium

7. In Vivo Cellular and Molecular Imaging labVrije Universiteit Brussel Brussels Belgium

Funder

Fonds Wetenschappelijk Onderzoek

Publisher

Wiley

Subject

General Chemistry,Catalysis,Organic Chemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/chem.201701321

Reference43 articles.

2. Distinct antibody species: structural differences creating therapeutic opportunities

3. Nanobodies to Study G Protein–Coupled Receptor Structure and Function

4. Naturally occurring antibodies devoid of light chains

5. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Computational Modeling and Characterization of Peptides Derived from Nanobody Complementary-Determining Region 2 (CDR2) Targeting Active-State Conformation of the β2-Adrenergic Receptor (β2AR);Biomolecules;2024-03-30

2. Development of Nanobodies as Theranostic Agents against CMY-2-Like Class C β-Lactamases;Antimicrobial Agents and Chemotherapy;2023-04-18

3. Intracellular VHHs to monitor and modulate GPCR signaling;Frontiers in Endocrinology;2022-11-16

4. Development of nanobodies as theranostic agents against CMY-2-like class C β-lactamases;2022-07-03

5. Downsizing antibodies: Towards complementarity-determining region (CDR)-based peptide mimetics;Bioorganic Chemistry;2022-02